The interim results of the ADAURA trial demonstrate that osimertinib has a definite role in treating resectable epidermal growth factor receptor (EGFR)‐mutated NSCLC after completion of curative‐intent surgery and adjuvant chemotherapy.8, 9, 10, 11, 12. Here, EGFR is linked to non-small cell lung carcinoma.